UCBJF News and Press, UCB SA

2026-02-28 00:47:47 ET UCB SA (UCBJY) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST Company Participants Antje Witte - Head of Investor Relations Jean-Christophe Tellier - CEO & Executive Director Emmanuel Caeymaex - Executive Vice President of Patient Ev...

2026-02-26 01:51:02 ET More on UCB SA UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Seeking Alpha’s Quant Rating on UCB SA Histor...

2026-02-16 06:15:04 ET Goldman Sachs analyst issues BUY recommendation for UCBJF on February 16, 2026 11:24AM ET. The previous analyst recommendation was Buy. UCBJF was trading at $335.24 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...

2026-01-14 12:46:00 ET UCB SA (UCBJY) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-06 13:30:04 ET Barclays analyst issues OVERWEIGHT recommendation for UCBJF on January 6, 2026 06:48PM ET. The previous analyst recommendation was Overweight. UCBJF was trading at $268.71 at issue of the analyst recommendation. The overall analyst consensus : BUY....

2025-12-10 10:26:49 ET Introduction AstraZeneca ( AZN ) is looking to be the first biopharma to throw off the cloak of cyclicality due to their work in optimizing the commercial and pipeline asset base. Despite being able to leverage experience and economies of scale, big pharma...

2025-11-16 14:31:00 ET ... Read the full article on Seeking Alpha For further details see: PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

2025-09-30 13:34:03 ET More on MoonLake Immunotherapeutics MoonLake: From 'Best-In-Class' Hopes To Approvability Debate (Rating Downgrade) MoonLake Immunotherapeutics (MLTX) RND Day Conference Call (Transcript) MoonLake Immunotherapeutics (MLTX) RND Day Conference Pr...

2025-09-24 10:17:30 ET It's been just over three months since my last article on Amgen Inc. (AMGN), "Amgen: Imdelltra Data and Q1 Results Impressive."... Read the full article on Seeking Alpha For further details see: Amgen: Imdelltra Could Be The Next Game Changer

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress PR Newswire 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living w...